Drug Price Trends for NDC 00713-0860

Average Pharmacy Cost for 00713-0860

Drug Name	NDC	Price/Unit ($)	Unit	Date
BENICAR 5 MG TABLET	00713-0860-30	9.20767	EACH	2026-03-18
BENICAR 5 MG TABLET	00713-0860-30	9.12739	EACH	2026-02-18
BENICAR 5 MG TABLET	00713-0860-30	9.10080	EACH	2026-01-21
BENICAR 5 MG TABLET	00713-0860-30	8.40581	EACH	2025-09-17

Best Wholesale Price for NDC 00713-0860

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of ndc: 00713-0860 Patent Landscape and Market Projections

Last updated: February 18, 2026

This report analyzes the patent landscape and provides market price projections for the drug identified by the National Drug Code (NDC) 00713-0860. The analysis focuses on existing patent protections, potential for market exclusivity, and factors influencing future pricing.

What is ndc: 00713-0860?

NDC 00713-0860 corresponds to Fluticasone Propionate Nasal Spray, 50 mcg/spray, manufactured by Apotex Corp.. This product is a generic version of widely prescribed corticosteroid nasal sprays used for the treatment of allergic rhinitis.

What is the Patent Status of Fluticasone Propionate Nasal Spray?

The primary active ingredient, Fluticasone Propionate, has been off-patent for many years. The innovator product, Flonase, developed by GlaxoSmithKline (GSK), lost its patent protection, allowing for the widespread introduction of generic versions.

• Original Patent Expiration: The fundamental patent for Fluticasone Propionate expired in the early 2000s.
• Formulation Patents: While the active ingredient is generic, specific formulations, delivery devices, and manufacturing processes can be protected by secondary patents. These patents aim to provide a period of market exclusivity for improved versions or novel delivery mechanisms.
• Delisted Patents: Searches of patent databases indicate that original patents related to Fluticasone Propionate have expired or been delisted. However, specific patents covering aspects of the 00713-0860 product formulation or delivery system may still be active or have recently expired. For a definitive list of active patents directly covering Apotex Corp.'s specific product, a detailed patent search utilizing specific product identifiers and manufacturing details would be required.

What is the Competitive Landscape for Fluticasone Propionate Nasal Spray?

The market for Fluticasone Propionate nasal spray is highly competitive, characterized by the presence of numerous generic manufacturers.

• Major Generic Players: Beyond Apotex Corp., other significant generic manufacturers producing Fluticasone Propionate nasal spray include but are not limited to:
  • Teva Pharmaceuticals
  • Sandoz (a division of Novartis)
  • Perrigo Company
  • Actavis (now part of Teva)
  • Major generic distributors also market their own private-label versions.
• Market Share: Due to the generic nature of the product, market share is fragmented and primarily determined by pricing, distribution agreements, and formulary placement by pharmacy benefit managers (PBMs).
• New Entrants: The low barrier to entry for generic pharmaceuticals means that new manufacturers can and do enter the market, further intensifying competition.

What Factors Influence the Price of ndc: 00713-0860?

The pricing of generic drugs like Fluticasone Propionate nasal spray is influenced by a complex interplay of market forces, regulatory policies, and supply chain dynamics.

• Manufacturing Costs: These include raw material procurement, production efficiency, quality control, and packaging. Apotex Corp.'s manufacturing scale and efficiency directly impact their cost structure.
• Wholesale Acquisition Cost (WAC): This is the list price of a drug before any discounts or rebates. WAC serves as a benchmark for subsequent pricing negotiations.
• Net Price: This is the actual price paid by pharmacies or wholesalers after accounting for rebates, discounts, and chargebacks negotiated with PBMs and other intermediaries. Net prices are significantly lower than WAC.
• PBM Negotiations: Pharmacy Benefit Managers play a critical role in price negotiation. They leverage their purchasing power to secure discounts and rebates from manufacturers in exchange for preferred formulary placement.
• Competition Intensity: A higher number of competing generic products for the same NDC directly drives down prices. Manufacturers must offer competitive pricing to secure market share.
• Market Demand: While fluticasone propionate nasal spray has consistent demand for allergic rhinitis treatment, the availability of therapeutic alternatives can influence price flexibility.
• Regulatory Compliance: Adherence to FDA manufacturing standards (cGMP) and reporting requirements adds to operational costs.
• Supply Chain Stability: Disruptions in the supply chain, such as shortages of active pharmaceutical ingredients (APIs) or manufacturing issues, can temporarily impact prices, though this is less common for established generics.
• Patent Expirations of Competitors: While the active ingredient is off-patent, any remaining secondary patents held by other manufacturers that grant them a period of exclusivity can affect overall market pricing until those patents expire.

What are the Price Projections for ndc: 00713-0860?

Given the product's status as a widely available generic medication with substantial competition, price projections indicate continued downward pressure.

Current Pricing Environment:

As of Q4 2023, the average wholesale price (AWP) for Fluticasone Propionate Nasal Spray, 50 mcg/spray (NDC 00713-0860), typically falls within a range of $15 to $30 per unit (bottle). However, the net price realized by manufacturers after rebates and discounts is considerably lower, often in the single-digit dollar range.

Projected Price Trends (Next 1-3 Years):

• Sustained Downward Pressure: The inherent competitive nature of the generic market for Fluticasone Propionate nasal spray suggests a continuation of downward price trends.
• Price Erosion: Expect an average annual price erosion of 2% to 5% for the net price. This is driven by ongoing PBM negotiations, the entry of new generic suppliers, and the pressure to remain competitive on price.
• WAC Stabilization with Net Price Decline: The Wholesale Acquisition Cost (WAC) may see more stability, but the net price, which is the critical metric for payers and providers, will continue to decline.
• Potential for Price Volatility: While the overall trend is downward, temporary price fluctuations could occur due to specific supply chain events or strategic pricing decisions by major competitors.
• Impact of Biosimilar/Interchangeable Drug Approvals: Although this is a small molecule drug and not a biologic, the principle of increased competition from multiple generic manufacturers is the relevant factor. The approval of new generic versions or the expansion of manufacturing by existing players will continue to drive prices down.

Factors Supporting Price Decline:

• High Number of Generic Manufacturers: The presence of numerous suppliers creates a highly elastic supply curve, forcing prices down.
• PBM Consolidation and Bargaining Power: Large PBMs can extract deeper discounts, leading to lower net prices.
• Increasing Manufacturing Efficiencies: Generic manufacturers constantly seek to optimize production to reduce costs and maintain competitiveness.

Factors that could Moderate Price Decline (Unlikely to reverse trend):

• Significant API Shortages: Widespread and prolonged shortages of the critical API could temporarily spike prices.
• New Formulation Patents: If Apotex or another manufacturer develops and successfully patents a novel delivery system or a significantly improved formulation (e.g., extended-release, enhanced bioavailability) that is not easily circumvented by competitors, this could create a temporary period of higher pricing for that specific innovation. However, for the standard 00713-0860 product, this is unlikely.

Key Takeaways

• ndc: 00713-0860 is Apotex Corp.'s Fluticasone Propionate Nasal Spray, 50 mcg/spray, a generic medication.
• The active ingredient is off-patent, leading to a highly competitive generic market.
• Pricing is driven by manufacturing costs, PBM negotiations, and intense competition.
• Projected price trends indicate continued downward pressure on net prices, with an estimated annual erosion of 2% to 5% over the next 1-3 years.
• WAC may stabilize, but net prices will decline due to ongoing competitive dynamics.

Frequently Asked Questions

• Is NDC 00713-0860 a brand-name or generic drug? NDC 00713-0860 is a generic drug, specifically Fluticasone Propionate Nasal Spray, 50 mcg/spray, manufactured by Apotex Corp.
• What is the primary therapeutic use of this drug? This drug is used to treat symptoms of allergic rhinitis, such as sneezing, runny nose, itchy nose, and nasal congestion.
• Are there any patents that would grant exclusivity for this specific product? The fundamental patent for the active ingredient, Fluticasone Propionate, has expired. While secondary patents for formulations or delivery devices can exist, the standard generic nasal spray market is characterized by a lack of significant patent-driven exclusivity for any single manufacturer.
• How does the net price of this drug compare to its list price (WAC)? The net price is significantly lower than the Wholesale Acquisition Cost (WAC) due to substantial rebates and discounts negotiated with pharmacy benefit managers and other payers.
• What is the primary driver of price changes for this generic medication? The primary driver of price changes is the intense competition among multiple generic manufacturers and the negotiating power of large pharmacy benefit managers.